Every 8-K that DiaMedica Therapeutics Inc. (DMAC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DMAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DMAC filings page.
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company focused on ischemic diseases, reported second quarter 2026 results and clinical progress for DM199. The company highlighted positive interim Part 1a Phase 2 data in women with preeclampsia, where mid-dose cohorts showed reductions in maternal blood pressure and uterine artery pulsatility index, supporting this dose range for further evaluation in early-onset preeclampsia and fetal growth restriction studies. A first fetal growth restriction cohort has been enrolled, and a concurrent open-label three-dose Phase 2 study in early-onset preeclampsia in North America and the United Kingdom is being prepared.
For the quarter ended June 30, 2026, research and development expenses were $8.2 million versus $5.8 million in 2025, and general and administrative expenses were $2.3 million versus $2.2 million. Net loss for the quarter was $10.1 million, compared with $7.7 million a year earlier, or $0.19 per share versus $0.18. For the first six months of 2026, net loss was $20.2 million versus $15.4 million in 2025. As of June 30, 2026, cash and cash equivalents were $5.1 million and marketable securities were $38.4 million, with total assets of $45.0 million and shareholders’ equity of $38.3 million. Net cash used in operating activities for the first half of 2026 was $17.2 million.
DiaMedica Therapeutics Inc. reported results from its 2026 Annual General Meeting of Shareholders. All seven incumbent directors were re-elected, with most nominees receiving over 10 million votes in favor. Shareholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026.
On an advisory basis, shareholders approved the company’s executive compensation, with 9,928,381 votes for and 271,093 against. They also approved an amendment to the Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares.
DiaMedica Therapeutics reported first quarter 2026 results with a higher net loss as it advanced its clinical programs in preeclampsia, fetal growth restriction and acute ischemic stroke.
Net loss was $10,042 thousand compared to $7,707 thousand a year earlier, driven mainly by increased research and development spending of $7,987 thousand versus $5,656 thousand. General and administrative expenses were stable at $2,495 thousand compared to $2,488 thousand.
Basic and diluted net loss per share was $0.19 on 53,793,490 weighted average shares, compared to $0.18 on 42,843,938 shares. As of March 31, 2026, cash and cash equivalents were $4,868 thousand and marketable securities were $46,463 thousand. Net cash used in operating activities was $9,082 thousand for the quarter.
DiaMedica Therapeutics Inc. reported full-year 2025 results showing a larger operating loss as it increased investment in its clinical pipeline while maintaining a strong cash position. Total operating expenses rose to 34,397 (in thousands) from 26,681 (in thousands), driven by higher research and development and general and administrative spending.
The company recorded a net loss of 32,766 (in thousands) for 2025 compared with 24,444 (in thousands) in 2024. As of December 31, 2025, cash and cash equivalents were 15,647 (in thousands) and marketable securities were 44,243 (in thousands), supported by 43,282 (in thousands) of net proceeds from common share issuances. Management expects this cash runway to fund operations through the second half of 2027 while advancing its DM199 programs in preeclampsia, fetal growth restriction, and acute ischemic stroke, including the ongoing ReMEDy2 Phase 2/3 trial and planned Phase 2 studies in early-onset preeclampsia.
DiaMedica Therapeutics Inc. reported an update on its DM199 preeclampsia program following a pre-IND meeting with the U.S. Food and Drug Administration. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model before proceeding with the planned study of DM199 in preeclampsia. Preparations for this new rabbit study have begun and results are expected to be available by the second quarter of 2026.
The company reiterates forward-looking statements about the potential clinical benefits of DM199 for preeclampsia and acute ischemic stroke, and notes that outcomes depend on future non-clinical and clinical results, regulatory feedback, funding, and operational factors such as site activation and enrollment in trials.
DiaMedica Therapeutics Inc. entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell, from time to time, up to $100.0 million of its common shares through an at-the-market program. TD Cowen will act as sales agent and may receive compensation of up to 3.0% of gross proceeds. Sales are to be made under the company’s Form S-3 shelf registration and may not occur until that registration is declared effective. The agreement contains customary representations, indemnities, and incorporated legal opinions from Pushor Mitchell and Alston & Bird.
DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the quarter ended June 30, 2025 and provided a business update via a press release attached as Exhibit 99.1 to this Form 8-K. The filing states the press release is furnished and incorporated by reference into Item 2.02, and expressly notes the information is not "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless specifically referenced. The company’s voting common shares trade on The Nasdaq Stock Market under the symbol DMAC. The 8-K lists Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page); the 8-K text itself contains no financial tables or line-item results, so readers must consult Exhibit 99.1 for detailed Q2 2025 figures and commentary.